- STAFF PICKS
- GIFTS + GIFT CARDS
- SELL BOOKS
- FIND A STORE
More copies of this ISBN
Other titles in the Contemporary Cardiology series:
Antithrombotic Drug Therapy in Cardiovascular Disease (Contemporary Cardiology)
Synopses & Reviews
Substantial morbidity and mortality remains associated with thrombotic events has stimulated the rapid expansion of the available armamentarium to combat pathologic thrombosis. Pathologic thrombosis plays an essential role in the pathogenesis of acute coronary syndromes (ACS), ischemic complications of percutaneous coronary intervention (PCI), venous thromboembolic disease, and embolic complications of arrhythmias and various cardiomyopathies. Written by experts in the field, Antithrombotic Drug Therapy in Cardiovascular Disease carefully examines individual and various combinations of the available antithrombotic regimens including fibrinolytic agents, antiplatelet therapies (aspirin, thieneopyridines, glycoprotein IIb/IIIa inhibitors), and anticogulant therapies (unfractionated heparin, low-molecular-weight heparins, direct thrombin inhibitors, and synthetic factor X inhibitors), non-ST-segment elevation (NSTE) ACS and ST-segment elevation myocardial infarction (STEMI). A detailed overview, Antithrombotic Drug Therapy in Cardiovascular Disease presents the evidence demonstrating the efficacy of available antithrombotic therapies in specific disease states such as atrial fibrillation, cardiomyopathy, valvular heart disease, and heparin-induced thrombocytopenia (HIT).
Book News Annotation:
Askari and Lincoff (cardiovascular medicine, Cleveland Clinic) compile 24 chapters that examine available antithrombotic regimens for interventions and treatment of diseases such as atrial fibrillation, cardiomyopathy, valvular heart disease, and heparin-induced thrombocytopenia. A group of cardiologists and cardiovascular medicine specialists from the US, Europe, and Canada discuss therapies individually and in combination, including fibrinolytic agents; antiplatelet therapies like aspirin, thieneopyridines, and glycoprotein IIb/IIIa inhibitors; anticoagulant therapies such as unfractionated heparin, low-molecular-weight heparins, direct thrombin inhibitors, and synthetic factor X inhibitors; and therapies for non-ST-segment elevation ACS and ST-segment elevation myocardial infarction. Pathophysiology and genetics of arterial and venous thrombosis, as well as the basic principles of thrombosis are addressed. Annotation ©2010 Book News, Inc., Portland, OR (booknews.com)
A thrombus, also called a blood clot, is an aggregation of platelets, fibrin, clotting factors, and the cellular elements of the blood attached to the interior wall of a vein or artery, sometimes occluding the lumen of the vessel. This book describes the mechanisms involved and how the various drugs work that have been developed to prevent and treat thrombi.
Written by experts in the field, this book provides a comprehensive overview of the pathophysiology, including the genetics, of arterial and venous thrombosis. It also presents the evidence demonstrating the efficacy of available antithrombotic therapies.
Table of Contents
Part 1: Basic Principles Chapter 1 The Platelet in Arterial and Venous Thrombosis Peter Kelly, MD Edward F. Plow, PhD Chapter 2 The Coagulation Cascade in Arterial and Venous Thrombosis Kandice Marchant, MD, PhD Chapter 3 The Link Between Thrombosis and Inflammation John H. Cleator, MD Mark Robbins, MD Chapter 4 Genetics of Thrombosis Svati H. Shah, MD, MHS Richard C. Becker, MD Part II: Antithrombotic Therapy for Stable Coronary Atherosclerotic Disease Chapter 5 Aspirin for Primary and Secondary Prevention Jinesh Kochar, MD, MPH J, Michael Gaziano, MD, MPH Chapter 6 Thienopyridines in Stable CAD Patients Dipak Kotecha, MBChB., MRCP. Marcus D. Flather, MBBS, FRCP Part III: Antithrombotic Therapy for NSTE ACS Chapter 7 Anti-platelet Therapies: Aspirin, Thienopyridines, and Glycoprotein IIb/IIIa Inhibitors Saif Anwaruddin MD Deepak L. Bhatt MD Chapter 8 Unfractionated Heparin and Enoxaparin Pierluigi Tricoci, MD, MHS, PhD Kenneth W. Mahaffey, MD Chapter 9 The Direct Thrombin Ihibitors Tyler Taigen, MD James Harvey, MD A. Michael Lincoff, MD Chapter 10 Synthetic Factor Xa Inhibition, Fondaparinux Michael S. Kim, MD Robert L. Page, Pharm.D Ivan P. Casserly, MBBCh Part IV: Antithrombotic Therapy for STEMI Chapter 11 Antiplatelet Therapies: Aspirin,Clopidogrel and thienopyridines and Glycoprotien IIb/IIIa Inhibitors Rory B. Weiner, MD Marc S. Sabatine, MD, MPH Chapter 12 Antithrombin Therapies: Unfractionated Heparin, Enoxaparin, Direct Thrombin Inhibitors, Fondaparinux John M. Galla, MD Arman T. Askari, MD Chapter 13 Fibrinolysis and Facilitated PCI Ryan D. Christofferson, MD Sorin J. Brener, MD Part V: Antithrombotic Therapy in Interventional Cardiology Chapter 14 Antithrombotic Therapy in Percutaneous Coronary Intervention Adrian W. Messerli, MD Chapter 15 Antithrombotic Therapy in Carotid and Peripheral Intervention Thomas J. Helton, MD Samir R. Kapadia, MD Chapter 16 Monitoring of Antithrombotic Therapies Kristofer Dosh, MD Steven Steinhubl, MD Part VI: Antithrombotic Therapy in Venous Thromboembolic Disease Chapter 17 Antithrombotic Therapy for DVT/PE Esther S.H. Kim, MD John R. Bartholomew, MD Chapter 18 Fibrinolysis for PE Stavros V. Konstantinides, MD Chapter 19 Duration of Anticoagulation Following VTE Clive Kearon, MB MRCPI FRCPC PhD Part VII: Clinical Considerations Chapter 20 Antithrombotic Therapy for Atrial Fibrillation Carmel M. Halley MD Allan L. Klein MD Chapter 21 Antithrombotic Therapy for Valvular Heart Disease Noah Rosenthal MD Brian D. Hoit MD Chapter 22 Antithrombotic Therapy for Cardiomyopathy Zuheir Abrahams MD PhD George Sokos MD W. H. Wilson Tang MD Chapter 23 Heparin-Induced Thrombocytopenia John R. Bartholomew, MD Chapter 24 "Resistance" to Antiplatelet Therapies Gerald C. Koenig, MD, PhD Hitinder S. Gurm, MD
What Our Readers Are Saying